
Activez les alertes d’offres d’emploi par e-mail !
Générez un CV personnalisé en quelques minutes
Décrochez un entretien et gagnez plus. En savoir plus
An international biotechnology company is seeking a Market Access Pricing and Public Affairs Director to lead the development of market access strategies for its oncology pipeline. This role requires 10 to 15 years of experience in market access, a strong network in France, and excellent negotiation skills. The director will oversee HTA submissions, drive public affairs planning, and collaborate with internal and external stakeholders to secure favorable pricing and access conditions. Fluency in the local language and business English is necessary.
Genmab is preparing to launch a new innovation in cervical cancer in Europe. In this role, you will lead development of the French Market Access strategy for the company’s oncology pipeline. Specifically, the Market access strategy, pricing and public affairs director will lead efforts in assessing and communicating to internal and external stakeholders the market access requirements of France for oncology, contributing to and shaping the overall value strategy for our brands throughout lifecycle. The position will drive development of local market access strategy, delivery of HTA submissions, and lead P&R negotiations. In this role, the director will also develop and implement a strong public affairs plan in collaboration with the GM.
Genmab maximizes the efficiency of an agile working environment, when possible, for the betterment of employee work‑life balance. Our offices are crafted as open, community‑based spaces that work to connect employees while being immersed in our powerful laboratories. Whether you’re in one of our office spaces or working remotely, we thrive on connecting with each other to innovate.
Genmab is an international biotechnology company with a core purpose to improve the lives of patients through innovative and differentiated antibody therapeutics. For 25 years, its hard‑working, innovative and collaborative team has invented next‑generation antibody technology platforms and harnessed translational, quantitative and data sciences, resulting in a proprietary pipeline including bispecific T‑cell engagers, antibody‑drug conjugates, next‑generation immune checkpoint modulators and effector‑function‑enhanced antibodies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with Knock‑Your‑Socks‑Off (KYSO®) antibody medicines.
Established in 1999, Genmab is headquartered in Copenhagen, Denmark with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn and X.
Genmab is committed to protecting your personal data and privacy. Please see our privacy policy for handling your data in connection with your application on our website Job Applicant Privacy Notice (genmab.com).
Please note that if you are applying for a position in the Netherlands, Genmab’s policy for all permanently budgeted hires in NL is initially to offer a fixed‑term employment contract for a year, if the employee performs well and if the business conditions do not change, renewal for an indefinite term may be considered after the contract.